Price T Rowe Associates Inc Arcellx, Inc. Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
A detailed history of Price T Rowe Associates Inc transactions in Arcellx, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 1,630,690 shares of ACLX stock, worth $132 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,630,690
Previous 1,344,553
21.28%
Holding current value
$132 Million
Previous $93.5 Million
3.76%
% of portfolio
0.01%
Previous 0.01%
Shares
7 transactions
Others Institutions Holding ACLX
# of Institutions
173Shares Held
45.6MCall Options Held
53.6KPut Options Held
53.7K-
Perceptive Advisors LLC New York, NY3.89MShares$314 Million6.21% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.85MShares$311 Million8.59% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$303 Million19.51% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$284 Million0.0% of portfolio
-
Sr One Capital Management, LP2.35MShares$190 Million56.87% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $3.54B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...